William Howard Sharfman
Johns Hopkins University · 141 works · 30,169 citations · h-index 46
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
- Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF V600 -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics
- Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain?
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus.
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
- The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin